---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-073609"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:30:27.095590+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health: 26% monthly volume growth, expanded Anthem & Medicaid, lower 2024 cash burn

## Summary
- OvaSuite product volume grew >26% in May 2024 vs January 2024; OvaWatch volume YTD up >88% vs 2023.
- Anthem contracts expanded to CT, NH, ME, adding 2M lives; total 9M Anthem lives, expects 16M more.
- Maryland and Kentucky added OvaWatch to Medicaid fee schedule at $897/test; nine states now cover OvaSuite.
- Philippines OvaWatch commercial launch on track for Q3 2024; fee-per-test model expected to yield higher margins.
- Company expects to lower 2024 cash used in operations guidance on Q2 2024 earnings call.

## SEC filing metadata
- accession: 0000950170-24-073609
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000095017024073609/0000950170-24-073609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000095017024073609/awh-20240613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-073609
- JSON: https://secwatch.observer/filing/0000950170-24-073609.json
- Plain text: https://secwatch.observer/filing/0000950170-24-073609.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.